FDA Warns Novo for Second Time About Misleading Ozempic Advertising

A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, on Oct. 31, 2023. Lee Smith/Reuters

The U.S. Food and Drug Administration has warned ‌Novo Nordisk over a consumer ad for its blockbuster diabetes drug, Ozempic, saying the commercial makes ‌false and misleading claims about the drug’s ⁠benefits.

It is the second time in less than a month that the FDA has warned the Danish drugmaker about its misleading ​ads.